key: cord-0849189-3qe5aq35
authors: Galván-Casas, C.; Català, A.; Muñoz-Santos, C.
title: SARS-CoV-2 Vaccines and the Skin
date: 2021-08-28
journal: Actas Dermosifiliogr
DOI: 10.1016/j.adengl.2021.07.028
sha: 1162e03e44fd1e00fb760fbe9aa01e5951d4aee2
doc_id: 849189
cord_uid: 3qe5aq35

Vaccines against the severe acute respiratory coronavirus 2, which are the first to be used in humans against any coronavirus, were developed and produced in record time. Dermatologic adverse effects appeared during clinical trials and have also been described in the population since approval. Just as descriptions and categorization of skin manifestations of the coronavirus disease 2019 proved important for understanding the disease itself, characterizing the effects of vaccines may also further that goal. This paper reviews the properties of the different types of vaccines currently available and under development and describes how they interact with the immune system and the clinical signs they may cause. We focus on dermatologic adverse effects reported to date and recommendations for managing them.

The lessons learned from other epidemics (Ebola, SARS-CoV, and MERS-CoV) and the international coordination of the knowledge generated have facilitate the global response to the COVID-19 pandemic. The COVID-NMA international research initiative, which arose from the WHO R&D plan, has facilitated the joint evaluation of a large number of clinical trials and of evidence on the prevention, treatment, and vaccines for the disease. This has made it possible to gain knowledge, make decisions, and achieve a vaccine, the essential tool for controlling the pandemic, in record time. 1, 2 Although such vaccines were being developed, to date, no effective vaccine had been used in humans against coronaviruses (CoV). Preclinical development was reached with SARS-CoV but was halted due to the disappearance of the virus as a health threat. But the similarity of the gene sequences of SARS-CoV-2 and SARS-CoV 3 reduced the time given over to design. Phase I/II clinical trials soon began and, based on the intermediate analysis of the results phase II trials were begun more quickly and with parallel trials. Before the studies were completed, production of several candidate vaccines had already begun. All this made it possible to have the vaccines available to inoculate the population with unimaginable speed. 1 The novel technology used and the speed of the process does not mean that the necessary safety controls were ignored. But it was to be expected, as we are seeing, that with clinical use, adverse effects would appear that were not found or were not sufficiently categorized during the preclinical phase. Cutaneous manifestations and their categorization were important for understanding the disease, 4 in the same way that those caused by the vaccines may be. 5 In many of these dermatologic manifestations associated with COVID-19, no sign was found of the virus or its direct cytopathic action, and they may be linked to the host immune response.

The authorization documents of all the available vaccines mentions the presence of dermatologic adverse effects and, after their clinical use, publications of various skin reactions continue to appear. As dermatologists, it is important to understand the characteristics of the different types of vaccine, their interaction with the host, and the range of systemic and dermatologic reactions that we may find.

SARS-CoV-2 enters the host cell by binding to the angiotensin converting enzyme 2 (ACE2) by means of its surface spike (S) protein. In the host, SARS-CoV-2 induces an innate immune response, with the participation of IFN-I and other proinflammatory cytokines, and an adaptive immune response, in which T CD4+ and CD8+ lymphocytes react against the viral proteins S, M, and N, Nsp, and ORF3a. In the mucosa of the upper respiratory tract, contact with the virus induces the formation of secretory IgA. At the systemic level, IgG specifies against the S protein and the protein of its receptor-binding domain (RBD) is recruited from the serum to the lower respiratory tract. The responses of serum IgM and IgA are less intense. 1, 6 The vaccines train the immune system using harmless SARS-CoV-2 antigens to stimulate an immune response without causing disease. Following intramuscular administration, they essentially induce humoral immunity but are not able to improve the local response. Those administered intranasally induce a potentially sterilizing lgAdependent local immunity but induce less effective systemic immunity. Some vaccines use adjuvants to activate the cell receptors and induce an innate immune response locally and in the regional lymph nodes, or to polarize the type of immune response desired. They improve the immune response but they also increase reactions to the vaccine. 6,7 Both inactivated-virus vaccines and protein-based viruses are formulated with adjuvants.

Each vaccine introduces one type of antigen, triggering a specific immune response that, in turn, generates the immune memory that makes it possible to combat SARS-CoV-2 in the event of future exposure. This antigen is processed by the antigen-presenting cells and is presented to the CD8+ and CD4+ T cells. Th1 cytokines also stimulate the CD8+ T cells and Th2 cytokines induce the production of neutralizing antibodies by the B cells.

All the vaccines induce some level of inflammation triggered by the activation of the innate immune response. 8 The imbalance of these responses may give rise to inflammatory reactions, 6 which can manifest in the skin.

Anti-protein S antibodies inhibit the SARS-CoV-2-ACE-2 bond and the development of vaccines has thus focused on antigens derived from the S protein. The different forms used by the vaccines to introduce the antigen are shown in Figure 1 . And the different characteristics of the main vaccines available and under development are shown in Table 1 .

Reactogenicity or the physical manifestation of the inflammatory response may present as a local reaction at the injection site (pain, heat, reddening, swelling, hardness) and/or with systemic symptoms (fever, myalgia, headache, etc.). The sequence of reactions induced from the moment of contact with the vaccine are shown in Figure 2 .

The tolerability and immunogenicity profile of the vaccines varies depending on the type of antigen and the adjuvant used. RNA vaccines (potent activator of the innate immune response) induce frequent, though mild, adverse reactions. Other factors that modify these effects are age (more reactogenicity in young people), a high body mass index (perhaps linked to a poor subcutaneous injection technique), pre-existing immunity, the route and site of administration, the injection technique, sex (more reactogenicity in women), some genetic and racial factors, and anxiety.

The clinical trials prior to approval of the available vaccines notified adverse effects, including skin reactions, sometimes with little details, which are summarized in Table  2 . [9] [10] [11] [12] Cutaneous adverse effects published after the vaccine reached the market are, partly, the same as those described in the clinical trials. These include the following:

This is the most commonly reported reaction. It involves the appearance of erythematous, edematous plaques of different sizes in the area where the vaccine was administered. These eruptions have been described with other vaccines, such as the combined pneumococcal vaccine. 13 fig. 3 The first published cases 8 appeared between 7 and 10 days after the first dose of the Moderna ® vaccine, which was initially attributed to a hypersensitive reaction to the polyethylene glycol contained in the vaccine. In another series, however, the intradermal test with polyethylene glycol polysorbate was only positive in one patient with a reaction that appeared only after the second dose. This does not support an IgEmediated reaction to these compounds as a cause. 14 Another study supports a delayed or T-cell mediated hypersensitivity reaction as a cause, based on the histopathology that showed the presence of superficial perivascular and perifollicular lymphocytic infiltrates with mastocytes and disperse eosinophils. 15, 16 A retrospective study analyzed the cutaneous reactions in a group of health workers vaccinated with the Pfizer ® vaccine. A delayed local reaction was observed in 2.1%, after both the first and second dose. As reported in other series, in half of cases, the reaction was repeated after the second dose. Two were biopsied and a superficial and deep perivascular lymphocyte infiltrate was found, with dilated vessels, intraluminal neutrophils, and immune staining negative for the SARS-CoV-2 spike protein 1A9. 17 All reported cases resolved with conservative treatment, such as local application of cold, topical corticosteroids, and/or antihistamines. No severe adverse reactions have been reported following the second dose and changing the guidelines is therefore not recommended. The appearance of erythema, edema, and nodules in areas that had previously been subjected to dermal fillers following processes such as viral infections or vaccines is well known, 18 and this has also been described in coincidence with SARS-CoV-2 infection and in some isolated cases after vaccination against COVID-19. 19, 20 Taking into account the number of vaccines administered globally and the number of people who have dermal fillers, it seems likely that the frequency is very los. 21 fig. 4 A suggested pathophysiological mechanism is a cascade of events that begins with deficient phagocytosis of the hyaluronic acid, formation of a biofilm around the filler material, activation of T cells, and formation of fibrosis and granulomas. These alterations favor the presence of Th1/CD8+ T cells and the high concentrations of ACE2 in the resident cells. This would lead to abnormal regulation between the production of proinflammatory angiotensin II and anti-inflammatory angiotensin I. The binding of the S protein to ACE2, induced by the vaccine, would tilt the balance toward inflammation. In 5 cases, this hypothesis justified treatment of these reactions by blocking the angiotensin II with an ACE inhibitor, with good results. The authors recommend lisinopril 5░mg/d, doubling the dosage if no improvement is achieved in 72░hours and pretreatment before the second dose of the vaccine of patients who presented this complication after the first dose.

It is important to bear in mind that, although there are currently few cases, all those reported have evolved favorably regardless of the prescribed treatment, which has been highly diverse. Cases have been reported that were treated with systemic antihistamines, antibiotics, or corticosteroids, intralesional corticosteroids and 5-fluorouracil, and injections of hyaluronidase. A more thorough understanding and broader experience are doubtless necessary before reaching conclusions.

O t h e r C u t a n e o u s E r u p t i o n s As with COVID-19, a wide variety of cutaneous manifestations have been reported coinciding with vaccination and with no other apparent cause. Morbilliform eruptions, 15 urticarial eruptions, 17 maculopapular eruptions, 22 lichen planus, 23,24 erythema multiforme, 25 and reactivations of herpes zoster. 26 These data corroborate the recent publication of 414 reactions following the Moderna ® and Pfizer ® vaccines reported by different health care professionals through the register of SARS-CoV-2 cutaneous manifestations of the American Academy of Dermatology. No severe reactions were found and half of patients with reactions following the first dose did not present these reactions after the second dose. Different reactions have been added, which were J o u r n a l P r e -p r o o f observed both after the first dose and after the second dose, such as erythromelalgia and perniosis. 27 O t h e r Ma n i f e s t a t i o n s Self-limiting enlarged supraclavicular lymph nodes have been reported and have been linked to the injection at an inappropriate site, higher than recommended (2-3 fingers below the acromion) 28 and rare anaphylactic reactions with no fatalities 29 but in a higher percentage than with the usual vaccines (4.2 cases per million compared to 1 case per million).

The CDC has issued recommendations for mRNA vaccines, about when to give a green light, take precautions, or avoid administering them, which are summarized in Figure 5 . Although most patients who have had anaphylactic reactions have a history of allergies, 30 atopic patients with rash and with eczema, while they should be correctly treated at the moment of vaccination, should not delay vaccination, and do not have an increased risk of severe allergic reactions. 31 

As occurred with the COVID-19 emergency, the mass administration to the population of a newly created vaccine and technology is bringing to light a wide variety of cutaneous manifestations. As dermatologists, it is our mission to be watchful, to analyze, categorize, evaluate the significance and the consequences of each manifestation, and communicate our findings to the pharmacovigilance bodies and to the scientific community.

With this goal and with the support of the Spanish Academy of Dermatology, may dermatologists in Spain have proposed recording as many dermatologic adverse effects as possible.

At present, most of the more than 100 cases reported correspond to women and to the Pfizer vaccine ® . A similar number of effects have been reported after the first dose and after the second dose. The most frequent manifestations are covid-arm, urticarial eruptions, and reactivation of herpes zoster. Information: vacunascovidpiel@gmail.com; https://aedv.es/reacciones-cutaneas-tras-la -administracion-de-vacunas-frente-a-sars-cov-2/

The vaccines have a proven safety profile. Nevertheless, they do present systemic and local reactions that we should be aware of.

The correct categorization of cutaneous reactions to the vaccines will make it possible to provide adequate information to our patients, prevent unnecessary rejection of vaccination, reduce severe adverse effects in predisposed individuals, and gain a deeper understanding of the pathophysiological mechanisms underlying the immune reaction to SARS-CoV-2.

This study has not received funding of any kind.

The authors declare that they have no conflicts of interest. 

SARS-CoV-2 vaccines in development

The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic

Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection

Classification of the cutaneous manifestations of COVID -19: a rapid prospective nationwide consensus study in Spain with 375 cases

Heterogeneity in reported skin manifestations of COVID-19 and vaccines

A systematic review of SARS-CoV-2 vaccine candidates

Recombinant protein vaccines, a proven approach against coronavirus pandemics

The how's and what's of vaccine reactogenicity

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination

Polyethylene Glycol and Polysorbate Skin Testing in the Evaluation of COVID-19 Vaccine Reactions: Early Report

COVID arm": A reaction to the Moderna vaccine

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers

Retrospective review of del ayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients

Hypersensitivity reaction to Hyaluronic Acid Dermal filler following novel Coronavirus infection -a case report

COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment

Oral angiotensinconverting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation

Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine

COVID-19 "second wave" and vaccines: the dermatologists' perspective

Lichen planus arising after COVID-19 vaccination

Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination

Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases -practical recommendations. A position statement of ETFAD with external experts

Mechanism of action of mRNA-based vaccines

Advances in mRNA Vaccines for Infectious

The authors would like to thank the Spanish Academy of Dermatology for its support, Álvaro Frías Sánchez for the graphics, and José Luis Martínez Amo for allowing the use of Figure 4 .Agradecimientos: a la Academia Española de dermatología por su apoyo, a Álvaro Frías Sánchez por la elaboración de los gráficos y a José Luis Martínez Amo por ceder la figura 4.

Particles similar to viruses that to not have a genome but express S protein on the surface Vectores virales que expresan la proteína sin capacidad de propagarse en las células del receptor (replicación incompetente) Viral vectors that express the S protein without the ability to replicated in receptor cells (incompetent replication) Vectores virales que expresan la proteína S, con capacidad de propagarse en las células del receptor (replicación competente) Viral vectors that express the S protein without the ability to replicated in receptor cells (incompetent replication) Vectores virales inactivados que expresan la proteína S Inactivated viral vectors that express the S protein Plásmidos de ADN que codifican la proteína S DNA plasmids that code for the S protein ARN que, igual que la anterior, aporta la información genética en vez del antígeno, mediante ARNm (mensajero) o ARN autorreplicable.RNA that, like the previous one, provide genetic information instead of the antigen, using mRNA (messenger RNA) or self-replicating RNA.

Inoculación de la vacuna, estimulo inmunogénico. Los adyuvantes aumentan esta reactividad local Inoculation of the vaccine, immunogenic stimulus. Adjuvants increase this local reactivity. Los macrófagos y los mastocitos inician una respuesta con liberación de citocinas proinflamatorias (IL-1, IL-6. TNF-a), quimiocinas, complemento (C3a y C5a) y vasodilatadores (aminas vasoactivas y bradicinina). Los mediadores vuelven a su nivel basal en 72 horas.Macrophages and mastocytes initiate a response with release of proinflammatory cytokines (IL-1, IL-6, TNF-a), chemokines, complement (C3a and C5a), and vasodilators (vasoactive amines and bradykinin). The mediators return to baseline leve in 72 hours. Los neutrófilos y los monocitos infiltran los tejidos expuestos y vuelven a su nivel basal tras 5-7 días. Los ganglios linfáticos de drenaje también expresan citocinas y quimiocinas unas horas tras la inyección. Las células dendríticas, eosinófilos, células NK y linfocitos, se reclutan más tarde.Neutrophils and monocytes infiltrate the exposed tissue and return to baseline levels after 5-7 days. Lymph nodes also express cytokines and chemokines a few hours after injection. Dendritic cells, eosinophils, NK cells and lymphocytes are recruited later.

Los mediadores y productos de inflamación circulantes actúan también en órganos distantes y pueden causar efectos sistémicos Mediators and circulating inflammation products also act on distant organs and may cause systemic effects. Estas fases pueden acompañarse de los siguientes síntomas: dolor, calor, hinchazón, eritema, adenopatía axilar dolorosa, fiebre, fatiga, cefalea, artralgias, sensación gripal o erupciones cutáneas.These phases may be accompanied by the following symptoms: pain, heat, swelling, erythema, painful enlarged axillary lymph nodes, fever, fatigue, headache, joint pain, flu sensation, or cutaneous eruptions.